Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/15/2024 | $110.00 | Outperform | Wolfe Research | |
| 11/14/2024 | $125.00 | Buy | Citigroup | |
| 11/8/2024 | Buy → Hold | Maxim Group | ||
| 10/21/2024 | $74.00 → $96.00 | Market Perform → Outperform | Leerink Partners | |
| 10/17/2024 | $105.00 | Outperform | Bernstein | |
| 10/7/2024 | $78.00 → $100.00 | Equal Weight → Overweight | Wells Fargo | |
| 9/23/2024 | $36.00 → $43.00 | Neutral → Buy | Citigroup | |
| 9/12/2024 | $1000.00 | Overweight | Wells Fargo |
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
8-K - BlackRock, Inc. (0002012383) (Filer)
424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)
SC 13G/A - BlackRock, Inc. (0002012383) (Filed by)
SC 13G - BlackRock, Inc. (0002012383) (Subject)
SC 13G/A - Keurig Dr Pepper Inc. (0001418135) (Subject)
TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited ("BlackRock Canada"), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE:BLK), today announced the estimated 2024 annual reinvested capital gains distributions for the iShares ETFs listed on the TSX or Cboe Canada.Please note that these are estimated capital gains amounts only, as of October 31, 2024. As these are estimated amounts, the final capital gains distributions may change by the Funds' December 15, 2024 or December 31, 2024, in the case of iShares Premium Money Market ETF ("CMR"), tax year-ends. These estimates are for the annual non-cash capital gains distributions, which are typica
BlackRock, Inc. (NYSE:BLK) today announced that its Board of Directors has declared a quarterly cash dividend of $5.10 per share of common stock, payable December 23, 2024 to shareholders of record at the close of business on December 5, 2024. About BlackRock BlackRock's purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate. View source version on businesswire.com: https://www.businessw
The BlackRock International Dividend ETF (BIDD) is BlackRock's first active mutual fund converted ETF Consistent historical outperformance led by all-female portfolio management team1 Today, BlackRock announced the successful conversion of the BlackRock International Dividend Fund into an active ETF, creating the BlackRock International Dividend ETF (NYSE:BIDD). This marks a significant milestone as the firm's first active mutual fund to active ETF conversion, catering to the growing preference among U.S. investors for the ETF structure. It is also BlackRock's first U.S.-listed active ETF that provides access to high-quality dividend-paying companies across international developed and e
Wolfe Research initiated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $110.00
Citigroup initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $125.00
Maxim Group downgraded Gilead Sciences from Buy to Hold
4 - Keurig Dr Pepper Inc. (0001418135) (Issuer)
4 - Keurig Dr Pepper Inc. (0001418135) (Issuer)
4 - Keurig Dr Pepper Inc. (0001418135) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
3 - Keurig Dr Pepper Inc. (0001418135) (Issuer)
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-20) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 10/08/2024. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)
TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited ("BlackRock Canada"), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE:BLK), today announced the final November 2024 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on November 21, 2024 will receive cash distributions payable on December 2, 2024. Details regarding the final "per unit" distribution amounts are as follows: Fund NameFund Ticker Cash Distribution Per Unit iShares Premium Money Market ETFCMR$0.138 Further information on the iShares ETFs can be found at http://www.blackrock.com/ca. About BlackRock BlackRock's purpose is to help more and more peo
TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited ("BlackRock Canada"), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE:BLK), today announced the estimated 2024 annual reinvested capital gains distributions for the iShares ETFs listed on the TSX or Cboe Canada.Please note that these are estimated capital gains amounts only, as of October 31, 2024. As these are estimated amounts, the final capital gains distributions may change by the Funds' December 15, 2024 or December 31, 2024, in the case of iShares Premium Money Market ETF ("CMR"), tax year-ends. These estimates are for the annual non-cash capital gains distributions, which are typica
BURLINGTON, Mass. and FRISCO, Texas, Nov. 20, 2024 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ:KDP) today announced that Tim Cofer, Chief Executive Officer, and Sudhanshu Priyadarshi, Chief Financial Officer and President, International, will participate in a fireside chat at the Morgan Stanley Global Consumer & Retail Conference on December 4, 2024 at 10:15 AM ET. Access to a live webcast of the event will be available on the Company's corporate website, www.keurigdrpepper.com. For those unable to join the live webcast, a recorded version of the event, as well as a transcript, will be made available through the Investors section of KDP's website. Investor Contacts: Investor RelationsT: 88
Company elevates digital-first capabilities as part of consumer-obsessed strategy BURLINGTON, Mass. and FRISCO, Texas, Nov. 11, 2024 /PRNewswire/ -- Keurig Dr Pepper (NASDAQ:KDP) announced the appointment of Drew Panayiotou as Chief Marketing Officer (CMO), U.S. Refreshment Beverages, effective today. Panayiotou brings a modern approach to marketing and a broad range of experience to the role, having led teams at agencies and across multiple industries, including beverages, technology, health care, retail and entertainment. Andrew Springate, who currently serves as CMO for U
Tim Cofer Appointed CEO & Board Member Effective April 26; Bob Gamgort to Serve as Executive ChairmanFollowing Strong Q1, Company Continues to Expect On-Algorithm 2024 Net Sales and Adjusted EPS Growth BURLINGTON, Mass. and FRISCO, Texas, April 25, 2024 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ:KDP) today reported results for the first quarter of 2024, reaffirmed its full year guidance, and announced the completion of its CEO succession process. Reported GAAP Basis Adjusted Basis1 Q1 Q1 Net Sales $3.47 bn $3.47 bn % vs prior year 3.4 % 2.8 % Diluted EPS $0.33 $0.38 % vs prior year — % 11.8 % Commenting on this final step in the CEO transition, which began in Fall 2023, Chairman and CEO
Appoints Carrie Schroen to Lead Dedicated Team Focused on Next Phase of Growth Launches Digital Hub Serving Defined Contribution Advisors BlackRock today announced two major developments supporting the growth and advancement of defined contribution (DC) advisors. First, BlackRock has appointed Carrie Schroen as Head of US DC Intermediary Business, a newly created role, effective January 15, joining the already established leadership team for the business. Schroen most recently served as a national sales manager within BlackRock's U.S. Wealth Advisory team and brings more than 20 years of experience working with financial advisors, including starting her career as an advisor herself. S
High-rolling investors have positioned themselves bullish on Gilead Sciences (NASDAQ:GILD), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GILD often signals that someone has privileged information. Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment among these major traders is split, with 55% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $27,798, and 8 calls, totaling $322,062. Expe